Rituximab is not a “magic drug” in post-transplant recurrence of nephrotic syndrome

Pediatric patients with end-stage renal failure due to severe drug-resistant nephrotic syndrome are at risk of rapid recurrence after renal transplantation. Treatment options include plasmapheresis, high-dose of cyclosporine A/methylprednisolone and more recently—rituximab (anti-B CD(20) monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales: Grenda, Ryszard, Jarmużek, Wioletta, Rubik, Jacek, Piątosa, Barbara, Prokurat, Sylwester
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005389/
https://www.ncbi.nlm.nih.gov/pubmed/27364906
http://dx.doi.org/10.1007/s00431-016-2747-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005389/
https://www.ncbi.nlm.nih.gov/pubmed/27364906
http://dx.doi.org/10.1007/s00431-016-2747-1

Ejemplares similares